Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaGlobeNewsWire • 10/22/26
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual MeetingGlobeNewsWire • 10/19/26
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM BreakthroughSeeking Alpha • 09/04/26
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple ExpansionsGlobeNewsWire • 08/31/26
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for SuccessGlobeNewsWire • 07/21/26
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer CenterGlobeNewsWire • 07/15/26
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in IsraelGlobeNewsWire • 06/23/26
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease ControlGlobeNewsWire • 06/11/26
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer PatientsGlobeNewsWire • 06/03/26
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual MeetingGlobeNewsWire • 06/01/26
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/18/26
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma StudyMarketBeat • 05/11/26
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ETGlobeNewsWire • 05/11/26
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent GlioblastomaGlobeNewsWire • 05/08/26
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 05/08/26
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas InstituteGlobeNewsWire • 05/07/26